CELESTONE SOLUSPAN Rx
Generic Name and Formulations:
Betamethasone sodium phosphate 3mg/mL, betamethasone acetate 3mg/mL; susp for IM, intra-articular or intralesional inj; contains benzalkonium chloride.
Merck & Co., Inc.
Indications for CELESTONE SOLUSPAN:
Steroid-responsive disorders when oral therapy not feasible.
See full labeling. Individualize. Titrate to lowest effective dose. Usual range: 0.25–9mg/day.
See full labeling. Individualize. Titrate to lowest effective dose. Initially 0.02–0.3mg/kg/day in 3 or 4 divided doses.
IM inj with idiopathic thrombocytopenic purpura.
Avoid IV administration. Not for treating traumatic brain injury or optic neuritis. Not for epidural use; serious neurologic events may occur. Concomitant systemic fungal infections, active ocular herpes simplex, cerebral malaria, live vaccines, previously injected joint: not recommended. Latent or active amebiasis. Strongyloides infection. Tuberculosis. If exposed to chickenpox or measles, consider prophylactic immunoglobulin therapy; consider antiviral treatment if chickenpox develops. CHF. Recent MI. Hypertension. Fluid retention. Renal insufficiency. Peptic ulcers. Diverticulitis. Intestinal anastomoses. Ulcerative colitis. Cirrhosis. Unstable or infected joints; avoid. Postmenopausal women (osteoporosis risk). Supplement with additional steroids in physiologic stress. Emotional instability. Psychotic tendencies. Myasthenia gravis. Avoid abrupt cessation. Monitor BP, thyroid, weight, growth, fluid, electrolyte balance and intraocular pressure (w. therapy >6weeks). Pregnancy. Nursing mothers.
Potentiated by strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, macrolides, ritonavir, cobicistat-containing products), cyclosporine, estrogens. Antagonized by CYP3A4 inducers (eg, barbiturates, phenytoin, carbamazepine, rifampin), cholestyramine. May potentiate cyclosporine (seizure risk). May antagonize anticoagulants (monitor), isoniazid. Increased risk of arrhythmias with digitalis. May need to adjust dose of antidiabetic agents. Increased GI effects with aspirin, other NSAIDs. Monitor for hypokalemia with potassium-depleting drugs (eg, amphotericin B, diuretics). Concomitant neuromuscular blocking agents; increased risk of myopathy. Withdraw anticholinesterase agents at least 24hrs before initiating corticosteroid therapy. Aminoglutethimide may lead to loss of corticosteroid-induced adrenal suppression. May diminish response to vaccines with long-term use. May suppress reactions to skin tests.
HPA axis suppression, increased susceptibility to infection, glaucoma, cataracts, hypokalemia, hypocalcemia, hypernatremia, hypertension, thromboembolism, psychiatric effects, myopathy, osteoporosis, nausea, pancreatitis, peptic ulcer, dermal atrophy, increased sweating, impaired wound healing, increased intracranial pressure, carbohydrate and glucose intolerance, weight gain, inj site reactions, Kaposi's sarcoma, anaphylactoid reactions.
Multi-dose vial (5mL)—1
Neurology Advisor Articles
- FDA Approves Aimovig for Migraine Prevention
- Sports-Related Concussion Outcomes Predicted With Serum Neurofilament Light
- FDA: Lamotrigine Linked to Potentially Life-Threatening Adverse Reaction
- Prediction Algorithm Stratifies ICH Patients at Risk for Hematoma Expansion
- Psychological Therapies May Help Older Adults With Chronic Pain
- Amyloid Positivity Increases Risk for Cognitive Impairment in Dementia-Free Patients
- Valproic Acid-Related Adverse Fetal Outcomes May Be Linked to Placental Effects
- Risk of Dementia Up for Older Adults With Lowest Wealth
- Language Used in Medical Record Can Affect Patient Care
- Mortality in Alzheimer Disease Not Strongly Associated With Antipsychotics